

1 Obesity, hyperfiltration and early kidney damage: a new formula 2 for the estimation of creatinine clearance

3
4 Alessio Basolo^{1*}, Guido Salvetti^{1 *}, Domenico Giannese², Susanna Bechi Genzano¹, Giovanni
5 Ceccarini¹, Riccardo Giannini³, Gianluca Sotgia⁴, Paola Fierabracci¹, Paolo Piaggi⁵, Ferruccio
6 Santini¹
7

8 ¹ *Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Pisa, Italy.*

9 ² *Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy*

10 ³ *Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa,*
11 *Pisa, Italy*

12 ⁴ *Consorzio Metis, University Hospital of Pisa, Pisa 56124, PI, Italy*

13 ⁵ *Department of Information Engineering, University of Pisa, Pisa, Italy*
14

15 *: these authors contributed equally to the study

16 **E-mail addresses:** alessio.basolo@unipi.it; g.salvetti@int.med.unipi.it;
17 domenico.giannese@phd.unipi.it; susanna.bechi.dr@gmail.com; giovanni.ceccarini@unipi.it;
18 riccardo.giannini@unipi.it; g.sotgia@consorziometis.it; pfierab2001@yahoo.it;
19 paolo.piaggi@gmail.com; ferruccio.santini@unipi.it

20 21 **Corresponding author:**

22 Dr. Alessio Basolo
23 Obesity and Lipodystrophy Center
24 Endocrinology Unit
25 University Hospital of Pisa, 56124, Pisa, Italy
26 Telephone number: +39-050-995001
27 Fax number: +39-050-578772
28 ORCID: 0000-0001-6888-7080
29

30 **Keywords:**

31 Obesity, creatinine clearance, hyperfiltration, kidney damage
32

33 **Running title:**

34 Obesity and kidney function
35
36

37 **Funding**

38 This study was funded by the Italian Ministry of the University, Project code 2017L8Z2EM:
39 Mechanisms of adipose tissue dysfunction in obesity: a target of future weight loss strategies for
40 the prevention of diabetes and cardiovascular diseases.
41

1 **Disclosure summary**

2 The authors declare no conflict of interest.

3 **Abstract**

4

5 **Objective**

6 Glomerular hyperfiltration may represent a direct pathogenetic link between obesity and kidney
7 disease. The most widely used methods to estimate creatine clearance such as Cockcroft-Gault
8 (CG), Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease
9 Epidemiology Collaboration (CKD-EPI) have not been validated in subjects with obesity. The
10 performance of prediction formulas was compared to measured creatinine clearance (mCrCl) in
11 subjects with obesity.

12 **Methods**

13 The study population included 342 patients with obesity (mean BMI 47.6 kg/m²) without
14 primary kidney disease. A urine collection was performed over 24 hours for measurement of
15 CrCl.

16 **Results**

17 mCrCl increased with body weight. The CG formula showed an overestimation at high CrCl,
18 whereas an underestimation resulted from CKD-EPI and MDRD. To improve the accuracy of
19 estimated CrCl (eCrCl), a new CG-based formula was developed as follow:

20
$$53+0.7 \times (140-Age) \times Weight/(96 \times SCr) \times (0.85 \text{ if female})$$

21 A cut-off point for BMI of 32 Kg/m² was identified, at which the new formula may be applied to
22 improve eCrCl.

23 **Conclusions**

24 In patients with obesity the glomerular filtration rate increases with body weight, and it is
25 associated with the presence of albuminuria, suggesting an early kidney injury. We propose a

1 novel formula that improves the accuracy of eCrCl to avoid missed diagnoses of hyperfiltration
2 in patients with obesity.

3 **1. Introduction**

4 Obesity has become a worldwide epidemic and it is associated with various comorbidities
5 including type 2 diabetes, cardiovascular and chronic kidney diseases (CKD) ^{1, 2}. A high body
6 mass index (BMI) is one of the strongest risk factors for new-onset CKD ³. The glomerular
7 filtration rate (GFR) is defined as the volume of glomerular filtration per unit time and it is the
8 gold standard for the measurement of kidney function. An increased total GFR, named
9 glomerular hyperfiltration, is observed in a state of obesity ⁴ and it may represent a direct
10 pathogenetic link between obesity and kidney disease, possibly leading to renal function loss in
11 the long term, if left untreated ^{3, 5}. Several mechanisms have been proposed to explain the
12 pathogenesis of hyperfiltration, including hemodynamic changes associated with a
13 disequilibrium of vasoactive molecules that regulate the tone of afferent and efferent arterioles in
14 the glomeruli, increased renal blood flow ^{4, 5}, sodium reabsorption ^{6, 7}, activation of renin-
15 angiotensin-aldosterone system (RAAS) ⁸, secretion of hormones from the adipose tissue ^{9, 10},
16 inflammation ¹¹, and oxidative stress ¹². Hyperfiltration is considered a precursor of
17 intraglomerular hypertension that might induce albuminuria, an early sign of kidney injury ¹³. In
18 case of delayed detection, the presence of albumin in the urine may evolve to a state of
19 glomerulomegaly ¹⁴, glomerulosclerosis ¹⁵ and possibly to the development or progression of
20 nephropathy in the long term ¹³. In clinical practice, it is crucial to evaluate the kidney function
21 with the aim to identify the presence of kidney damage. The most accurate and precise
22 measurement of GFR (inulin clearance) is methodologically difficult in clinical settings (high
23 cost, complex protocol and time consuming). Although not very accurate and/or inconvenient for

1 clinicians and patients, other methods (creatinine clearance, urea, cystatin C and radioisotopic
2 methods) have been used in clinical or research settings to estimate the renal function ¹⁶. Thus,
3 prediction formulas using serum creatinine levels including *Cockcroft-Gault* (CG) ¹⁷,
4 *Modification of Diet in Renal Disease* (MDRD) ¹⁸ and *Chronic Kidney Disease Epidemiology*
5 *Collaboration* (CKD-EPI) ¹⁹ are currently the most widely used methods in routine clinical
6 practice as surrogates for the estimation of GFR. Yet, several studies suggest that estimated CrCl
7 (eCrCl) using CG, CKD and MDRD formulas is not accurate when compared to the
8 measurement of CrCl in subjects with obesity ²⁰⁻²². The lack of accuracy of eCrCl in obesity may
9 lead to missed diagnoses of hyperfiltration/early kidney disease that requires a prompt treatment
10 to avoid a progression to CKD and kidney failure over time. The aim of this study was to
11 evaluate the kidney function by comparing the eCrCl using the prediction formulas (CG, CKD-
12 EPI and MDRD) with measured CrCl (mCrCl) by 24 hours urine collection in a large population
13 of subjects with obesity. Eventually, we elaborated a new prediction formula for eCrCl in this
14 population at high risk for CKD.

16 2. Methods

17 2.1 Study populations

18 The study population included 342 patients with obesity (BMI 47.6 ± 8.9 kg/m² ranged from 30
19 to 96 kg/m², age 49.2 ± 12.5 years) evaluated at the Obesity and Lipodystrophy Center,
20 Endocrinology Unit, University Hospital of Pisa, Italy. At the time of the visit, 4% had class I
21 obesity, 13% had class II obesity and 83% had class III obesity (BMI > 40 kg/m²). Patients with
22 history of type 2 diabetes for more than 5 years and/or under insulin therapy and those with
23 primary kidney disease and/or with mCrCl <60 mL/min were excluded, as well as patients with

1 urine creatinine <950 mg/24 hours (suggestive of incomplete urine collection that may
2 underestimate CrCl).

3 All patients underwent measurement of body weight, height, systolic blood pressure (SBP) and
4 diastolic blood pressure (DBP). Body weight, in light clothing, was measured (to the nearest
5 0.1 kg) with digital electronic scale. Standing height, with no shoes, was measured (to the nearest
6 1 cm) using stadiometer. Body mass index (BMI) was calculated as the weight in kilograms
7 divided by the square of the height in meters. Overweight and obesity were classified according
8 to conventional definitions ²³. SBP and DBP were measured with an electronic device and the
9 average of two measurements in the sitting position with an interval of 2 minutes with an
10 appropriate cuff. Patients were classified as hypertensive when their blood pressure was >
11 140/90 mmHg or when they were on antihypertensive treatment at the time of blood pressure
12 measurement.

13 Blood samples were drawn in the fasting state in the morning for the measurement of serum
14 glucose, insulin and creatinine. A urine collection was performed over 24 hours for calculation of
15 CrCl as follows:

16 *Creatinine Clearance = (24 h urinary creatinine x Urinary volume) / Serum Creatinine*

17 eCrCl was calculated by the main formulas (**Table 1**) as previously described ¹⁷⁻¹⁹. It has to be
18 noted that CKD-EPI and MDRD formulas, at variance with CG, do not include body weight and
19 the results are normalized to 1.73 m² body surface area, which is an accepted average adult
20 surface area. In our cohort, eCrCl was estimated by using CKD-EPI and MDRD deindexed by
21 calculating the body surface area (BSA) of each patient (mean BSA = 2.31 m²) (**Table 1**). BSA
22 was calculated by the formula of Dubois and Dubois (0.0071843 × total body weight
23 [kilograms]^{0.425} × height [centimeters]^{0.725}) ²⁴. Albumin excretion in twenty-four-hour urine
24 volume was available in 182 patients. Publication of the study was approved by the Ethical

1 Committee (CEAVNO – Comitato Etico Area Vasta NordOvest) and, for policy of the
2 University Hospital, all patients signed an informed consent to use their clinical data for
3 scientific research.

4 An independent study group of 50 healthy individuals without obesity ($BMI < 30 \text{ kg/m}^2$, mean
5 $BMI = 23.9 \text{ kg/m}^2$) recruited at the Nephrology Unit as donors for kidney transplantation was
6 used for comparison.

7 **2.2 Statistical analysis**

8 Statistical analyses were performed using SAS software (SAS 9.3, Enterprise guide version 5.1;
9 SAS Institute, Cary, NC). Data are expressed as mean \pm SD or mean with 95% confidence interval
10 (CI). Shapiro-Wilk test was used to assess the normal distribution of the data. Albuminuria over
11 24 hours were log₁₀ transformed to meet the assumptions of linear regression (i.e.,
12 homoscedasticity and normal distribution). Associations between normally distributed
13 quantitative variables were assessed by the Pearson's correlation coefficient. Multivariate
14 regression analysis was used to evaluate the independent determinants of CrCl and albuminuria
15 by including age, sex, body weight, height, presence of diabetes and hypertension. Unpaired
16 Student's *t*-test were used to evaluate differences according to gender. Paired Student's *t*-test was
17 used to compare the measurement of CrCl and the estimation of creatinine clearance calculated
18 with the different formulas with the aim to identify the under or overestimation of the renal
19 function. A non-linear regression analysis was applied to the measured creatinine clearance data
20 to estimate the coefficient on the denominator of the CG formula (i.e., 72 in the original CG
21 formula) using the Levenberg-Marquardt algorithm^{25, 26}. This is an optimization method for
22 nonlinear least-squares problems, which combines the steepest descent method and the Gauss-
23 Newton method by introducing a damping parameter to control the balance between the two

1 methods. The CG formula with the new estimated coefficient (=96 by data fitting) was then
2 modified via linear regression analysis to have a zero intercept and a unitary slope with respect to
3 measured CrCl formula.

4 A cut-off point for BMI was identified at which the eCrCl calculated using the conventional CG
5 formula was, on average, 7 mL/min higher than the mCrCl. The value of 7 mL/min corresponds
6 to the average difference between the mCrCl and the modified CG equation.

8 **3. Results**

9 The anthropometric characteristics of the study population are shown in **Table 2**.

10 The mCrCl was positively associated with body weight ($r=0.40$, $p<0.0001$, **Figure 1A**) and
11 negatively related to age ($r=-0.40$, $p<0.0001$, **Figure 1B**). In a multivariate analysis including
12 age, gender, height, presence/absence of diabetes or hypertension, only body weight and age
13 were independent predictors of mCrCl ($\beta = 0.7$ ml/min per 1 kg, $p < 0.0001$; $\beta = -1.6$ ml/min per
14 1 year, $p=0.0001$, respectively).

15 In 182 patients in whom 24-hour albuminuria was available, a positive correlation with the
16 mCrCl was observed ($r=0.17$, $p=0.02$). In a multivariate analysis including age, body weight,
17 height, gender, presence/absence of diabetes and hypertension, mCrCl ($p=0.026$) and diabetes
18 ($p=0.03$) were both independent predictors of 24-hour albuminuria.

19 No significant effects could be demonstrated when systolic and diastolic blood pressure values
20 were added to the multivariate regression analyses.

21

22 **3.1 Comparison between mCrCl and eCrCl**

23 The results of eCrCl by current formulas are reported in **Table 2**.

1 The mCrCl was positively associated with eCrCl by CG ($r = 0.69$, $p < 0.01$, **Figure 2A**),
 2 deindexed CKD-EPI ($r = 0.66$, $p < 0.01$, **Figure 2B**) and deindexed MDRD ($r = 0.69$, $p < 0.01$,
 3 **Figure 2C**) prediction formulas. In our cohort, the CG formula showed a progressive
 4 overestimation at high CrCl values whereas an underestimation resulted from CKD-EPI and
 5 MDRD formulas. To further improve the precision of the eCrCl, starting from the CG formula
 6 that includes body weight in its algorithm, we generated a new coefficient ($= 96$ by data fitting)
 7 at the denominator (i.e., 72 in the original CG formula). The modified version of the CG formula
 8 was then adjusted via linear regression analysis to have a zero intercept and a unitary slope
 9 (**Figures 3 and 4**) with respect to the mCrCl as following:

$$10 \quad eCrCl = 53 + 0.7 \times \left[\frac{(140 - \text{Age}) \times (\text{Weight})}{96 \times \text{SCr}} \times 0.85(\text{if female}) \right]$$

11 where the eCrCl is expressed in mL/min, age in years, body weight in kg, serum creatinine (SCr)
 12 in mg/dL.

13 To define the cut-off of BMI in terms of appropriateness of the new equation, both the
 14 conventional CG equation and our modified CG formula were applied to calculate the eCrCl in
 15 an independent study group of 50 healthy individuals without obesity ($\text{BMI} < 30 \text{ kg/m}^2$, mean
 16 $\text{BMI} = 23.9 \text{ kg/m}^2$). In this group, we found that our modified formula has a significant
 17 proportional bias in predicting mCrCl (slope=1.77, 95% CI: 1.12-2.43, $p=0.02$ vs. slope=1),
 18 whereas the conventional CG equation does not (slope=0.93, $p=0.69$ vs. slope=1). These results
 19 indicate that our modified CG formula is not as accurate as the conventional CG equation for
 20 calculation of eCrCl in individuals without obesity. A cut-off of BMI greater than 32 kg/m^2
 21 (dotted line, Figure 5) was then identified as the value above which the conventional CG
 22 equation is expected to produce an overestimation of mCrCl, and the new formula may be
 23 applied to improve the estimation of CrCl in subjects with obesity.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

4. Discussion

In our population of patients with obesity without primary or overt kidney disease, mCrCl augmented with body weight, with an average increase of 0.7 mL/min per kg. This increase was associated with albumin excretion, suggesting a possible mechanism of early kidney damage. Although early renal damage may be the consequence of obesity-related comorbidities including diabetes mellitus or hypertension ²⁷, “healthy obesity” without evidence of coexisting cardiometabolic complications is an independent risk factor for renal injury ^{28, 29}, and glomerular hyperfiltration has been identified as a pathogenic link ⁵. The mechanisms leading to increased glomerular filtration in obesity may recognize an increase in the renal plasma flow and filtration fraction ⁷. The reduction of pre-glomerular vascular resistance along with a raise in post-glomerular resistance, lead to an increase in the filtering surface area thus increasing the permeability of the glomerular hydraulic barrier ⁵. The hemodynamic and the tubular hypothesis have been proposed as possible explanations for this cascade of events. The hemodynamic theory hypothesizes a disequilibrium of vasoactive molecules regulating the tone of afferent and efferent arterioles. The activation of the renin-angiotensin-aldosterone system (RAAS) with increased local production of angiotensin II ⁸ and activation of endothelin-1 contributes to increase the resistance of efferent arterioles. Additional molecules, such as cyclooxygenase 2 (COX2)-derived prostanoids and nitric oxide, have been identified as vasodilatory mediators, leading to a reduction in the afferent arteriolar resistance. The tubular theory hypothesizes that increased sodium reabsorption in the proximal tubule leads to a deactivation of the tubuloglomerular feedback ³⁰, causing a decrease in the afferent arteriole resistance, with consequent increase in the glomerular perfusion and filtration ⁵.

1 Important determinants of hyperfiltration include blood pressure, sodium intake and
2 consumption of meat protein [31](#). We could not demonstrate a direct effect of blood pressure,
3 extemporarily measured, on both CrCl and albuminuria, which may depend on the heterogeneity
4 of the studied population and on the effect of different antihypertensive drugs. Unfortunately,
5 due to the retrospective nature of the study, we did not have measures of 24h-urinary sodium and
6 24h-urinary urea reflecting sodium and protein intake, respectively. Prospective studies will be
7 necessary to define the effect size of these determinants on hyperfiltration in subjects with
8 obesity.

9 Additional mechanisms include the increase in serum leptin that may enhance the sympathetic
10 activity that, in turn, triggers RAAS activation and sodium retention in the kidney [5](#). Changes in
11 production of adiponectin [9](#) and resistin [32](#), inflammation [11](#), oxidative stress [12](#), abnormal lipid
12 metabolism [33](#), nephron mass reduction [14](#), insulin resistance [34](#), are further possible mechanisms
13 that may affect the glomerular filtration barrier, with consequent increase in glomerular
14 permeability. The first sign of renal damage is microalbuminuria, suggesting a potential risk of
15 progression to renal failure and the development of premature cardiovascular events, thus
16 worsening the prognosis in patients with obesity [35](#). Our results show that the mCrCl is
17 independently associated with albuminuria, suggesting a possible mechanism of early kidney
18 damage in patients with obesity. To which extent hyperfiltration, per se, may represent an early
19 sign of renal damage has not been fully clarified, yet, and the retrospective nature of our study
20 did not allow us to demonstrate the worsening of kidney damage or a potential progression to
21 kidney failure in our patients. The association of hyperfiltration with elevated urinary albumin
22 excretion has been already described [5](#). High prevalence of albuminuria was observed in a
23 population of patients with obesity undergoing bariatric surgery [36](#). In a cross-sectional study of

1 200 subjects with overweight and obesity, the prevalence of albuminuria was positively
2 associated with BMI ³⁷. Accordingly, a high prevalence of microalbuminuria (7.1%) or
3 macroalbuminuria (2.7%) has been observed in patients with overweight without diabetes or
4 hypertension ³⁸. In the NHANES 3, subjects with obesity showed higher prevalence of
5 albuminuria in comparison with the general population ³⁹. A decrease in GFR ⁴⁰, 24-h creatinine
6 clearance ⁴¹, albuminuria and proteinuria ^{40, 42} were observed following bariatric surgery.
7 Furthermore, adults with overweight and/or obesity, with no evidence of obesity-related
8 comorbidities, showed increased incidence of initial sign of kidney disease ⁴³. It has been
9 suggested that if hyperfiltration is not promptly treated, the initial glomerulomegaly may evolve
10 to glomerulosclerosis ¹⁴ and eventually to renal failure ⁴⁴.

11
12 Evaluation of the glomerular filtration rate in patients with obesity may therefore be important,
13 even in the absence of overt kidney disease, to establish whether tailored strategies for weight
14 loss and appropriate pharmacological therapies should be initiated for prevention of the renal
15 damage ⁴⁵. Several methods including inulin clearance ⁴⁶, radioisotopic methods, radiocontrast
16 agents, urea and cystatin C ¹⁶ have been used for the evaluation of kidney function. However,
17 these techniques show several disadvantages in the clinical practice due to potentially invasive,
18 time-consuming and complex or expensive methods of GFR assessment. The creatinine
19 clearance measurement by urine collection over 24 hours represents one of the most used
20 technique, although it results inconvenient due to difficulties for urine collection ¹⁶. To
21 encompass these difficulties, prediction equations such as CG ¹⁷, MDRD ¹⁸ and CKD-EPI ¹⁹ have
22 been developed for the estimation of CrCl in the general population. However, these prediction
23 formulas show lack of accuracy in the estimation of GFR in populations without chronic kidney

1 diseases compared to those with the disease ⁴⁷. Moreover, these formulas have not been validated
2 in patients with obesity, especially when BMI is >40 kg/m², in whom GFR estimation is
3 associated with important biases and inaccuracies ⁴⁸. Comorbidities such as diabetes and
4 hypertension may also impact on CrCl estimation ⁴⁹. To minimize the impact of these biases, in
5 our study we excluded patients with primary or overt kidney disease as well as those with
6 measured CrCl < 60 mL/min, with the aim at identifying patients with hyperfiltration, who may
7 need prompt specific therapeutic measures to slow down the progression of glomerular damage.
8 In our cohort, the CG formula showed a progressive overestimation at high CrCl values, whereas
9 an underestimation resulted from CKD-EPI and MDRD formulas. To further improve the
10 precision of the eCrCl, starting from CG formula that includes body weight in its algorithm, we
11 generated a new formula for the estimation of CrCl in our population of patients with obesity,
12 with a high correlation coefficient and no deviation at high mCrCl values.

13
14 Our study has some limitations. The study population comprised patients of Caucasian ethnicity
15 and it was predominantly composed by women. A proportion of patients were on treatment for
16 diabetes or hypertension, and 24-h albuminuria was not measured in the whole population.
17 Additionally, due to the retrospective nature of this study, data regarding patients' prognosis
18 were not available. Further studies will be necessary to address this issue.

19 **5. Conclusion**

20

21 In patients with obesity without primary or overt kidney damage, the glomerular filtration rate
22 increases with body weight, and it is associated with the presence of albuminuria, suggesting an
23 early kidney damage. We propose a new algorithm for the estimation of CrCl that might be

1 useful in clinical practice to identify a condition of hyperfiltration associated with obesity, with
2 the aim at detecting an early glomerular damage and preventing the progression of renal disease.

3

4

ACCEPTED MANUSCRIPT

1 **Acknowledgments**

2 None

3 **Author contributions**

4 A.B. and G.S. interpreted data and wrote the manuscript. D.G., P.P., P.F. and G.C. assisted with
5 the interpretation of the data and revised the manuscript. F.S. and G.S. designed the study
6 protocol. All authors read, critically revised the draft and approved the final manuscript. A.B. has
7 full access to all the data in the study and take responsibility for the integrity of the data and the
8 accuracy of the data analysis.

9
10 **Ethical approval**

11 The study was approved by the local Ethical Committee (CEAVNO – Comitato Etico Area Vasta
12 Nord-Ovest). All procedures performed in this study were in accordance with the ethical
13 standards of the Local Ethical Committee and with the 1964 Helsinki Declaration and its later
14 amendments.

15
16 **Data availability:**

17 Some or all datasets generated during and/or analyzed during the current study are not publicly
18 available but are available from the corresponding author on reasonable request

19
20 **References**

21 1. Ryan D, Barquera S, Barata Cavalcanti O, Ralston J. The Global Pandemic of
22 Overweight and Obesity: Addressing a Twenty-First Century Multifactorial Disease. *Handbook*
23 *of Global Health*. 2020:1-35.
24 2. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW, Gortmaker
25 SL. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *N Engl J Med*.
26 Dec 19 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301

- 1 3. Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo JJ, Tallam L. Is obesity a
2 major cause of chronic kidney disease? *Adv Ren Replace Ther.* Jan 2004;11(1):41-54.
3 doi:10.1053/j.arrt.2003.10.007
- 4 4. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular
5 hemodynamics in severe obesity. *Am J Physiol Renal Physiol.* May 2000;278(5):F817-22.
6 doi:10.1152/ajprenal.2000.278.5.F817
- 7 5. Cortinovis M, Perico N, Ruggenenti P, Remuzzi A, Remuzzi G. Glomerular
8 hyperfiltration. *Nat Rev Nephrol.* Jul 2022;18(7):435-451. doi:10.1038/s41581-022-00559-y
- 9 6. Pruijm M, Wuerzner G, Maillard M, Bovet P, Renaud C, Bochud M, Burnier M.
10 Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2
11 diabetes or impaired fasting glucose in a population of the African region. *Nephrol Dial*
12 *Transplant.* Jul 2010;25(7):2225-31. doi:10.1093/ndt/gfq008
- 13 7. Chagnac A, Herman M, Zingerman B, Erman A, Rozen-Zvi B, Hirsh J, Gafter U.
14 Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular
15 sodium reabsorption. *Nephrol Dial Transplant.* Dec 2008;23(12):3946-52.
16 doi:10.1093/ndt/gfn379
- 17 8. Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related
18 renal diseases. *Semin Nephrol.* Jan 2013;33(1):44-53. doi:10.1016/j.semnephrol.2012.12.002
- 19 9. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte
20 dysfunction. *Kidney Int.* Jul 2009;76(2):145-8. doi:10.1038/ki.2009.137
- 21 10. Shi Z, Li B, Brooks VL. Role of the Paraventricular Nucleus of the Hypothalamus in the
22 Sympathoexcitatory Effects of Leptin. *Hypertension.* Nov 2015;66(5):1034-41.
23 doi:10.1161/hypertensionaha.115.06017
- 24 11. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent
25 advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine*
26 *Netw.* Mar 2006;17(1):4-12.
- 27 12. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O,
28 Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on
29 metabolic syndrome. *J Clin Invest.* Dec 2004;114(12):1752-61. doi:10.1172/jci21625
- 30 13. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and
31 pre-hypertension. *Nephrol Dial Transplant.* May 2012;27(5):1708-14. doi:10.1093/ndt/gfs037
- 32 14. Tsuboi N, Okabayashi Y, Shimizu A, Yokoo T. The Renal Pathology of Obesity. *Kidney*
33 *Int Rep.* Mar 2017;2(2):251-260. doi:10.1016/j.ekir.2017.01.007
- 34 15. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related
35 glomerulopathy: an emerging epidemic. *Kidney Int.* Apr 2001;59(4):1498-509.
36 doi:10.1046/j.1523-1755.2001.0590041498.x
- 37 16. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical
38 practice. *Bmj.* Oct 7 2006;333(7571):733-7. doi:10.1136/bmj.38975.390370.7C
- 39 17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.
40 *Nephron.* 1976;16(1):31-41. doi:10.1159/000180580
- 41 18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van
42 Lente F. Using standardized serum creatinine values in the modification of diet in renal disease
43 study equation for estimating glomerular filtration rate. *Ann Intern Med.* Aug 15
44 2006;145(4):247-54. doi:10.7326/0003-4819-145-4-200608150-00004
- 45 19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW,
46 Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration

- 1 rate. *Ann Intern Med.* May 5 2009;150(9):604-12. doi:10.7326/0003-4819-150-9-200905050-
2 00006
- 3 20. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the
4 modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function.
5 *J Am Soc Nephrol.* Mar 2005;16(3):763-73. doi:10.1681/asn.2004070549
- 6 21. Domislovic M, Domislovic V, Fucek M, Jelakovic A, Gellineo L, Dika Z, Jelakovic B.
7 Should CKD EPI equation be used for estimation of glomerular filtration rate in obese subjects?
8 *Kidney Blood Press Res.* Sep 28 2022;doi:10.1159/000526115
- 9 22. Erstad BL, Nix DE. Assessment of Kidney Function in Patients With Extreme Obesity: A
10 Narrative Review. *Ann Pharmacother.* Jan 2021;55(1):80-88. doi:10.1177/1060028020935580
- 11 23. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels
12 SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The Science of
13 Obesity Management: An Endocrine Society Scientific Statement. *Endocr Rev.* Apr 1
14 2018;39(2):79-132. doi:10.1210/er.2017-00253
- 15 24. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and
16 weight be known. 1916. *Nutrition.* Sep-Oct 1989;5(5):303-11; discussion 312-3.
- 17 25. Levenberg K. A METHOD FOR THE SOLUTION OF CERTAIN NON – LINEAR
18 PROBLEMS IN LEAST SQUARES. *Quarterly of Applied Mathematics.* 1944;2:164-168.
- 19 26. Marquardt DW, duPont EI, R B, Burrell GC. Marquardt D W. An algorithm for least-
20 squares estimation of nonlinear parameters. *J. Soc. Indust. Appl. Math.* 11:431-41, 1963. 2004:
- 21 27. Kosmas CE, Silverio D, Tsomidou C, Salcedo MD, Montan PD, Guzman E. The Impact
22 of Insulin Resistance and Chronic Kidney Disease on Inflammation and Cardiovascular Disease.
23 *Clin Med Insights Endocrinol Diabetes.* 2018;11:1179551418792257.
24 doi:10.1177/1179551418792257
- 25 28. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and
26 kidney disease: a systematic review and meta-analysis. *Kidney Int.* Jan 2008;73(1):19-33.
27 doi:10.1038/sj.ki.5002586
- 28 29. Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: hidden consequences of
29 the epidemic. *Braz J Med Biol Res.* Apr 13 2017;50(5):e6075. doi:10.1590/1414-431x20166075
- 30 30. Schnermann J, Traynor T, Yang T, Arend L, Huang YG, Smart A, Briggs JP.
31 Tubuloglomerular feedback: new concepts and developments. *Kidney Int Suppl.* Sep
32 1998;67:S40-5. doi:10.1046/j.1523-1755.1998.06708.x
- 33 31. Hess B. 'Bad dietary habits' and recurrent calcium oxalate nephrolithiasis. *Nephrol Dial*
34 *Transplant.* Apr 1998;13(4):1033-8. doi:10.1093/ndt/13.4.1033
- 35 32. Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH, Jr., Kullo IJ.
36 Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive
37 adults. *Hypertension.* Oct 2007;50(4):708-14. doi:10.1161/hypertensionaha.107.095257
- 38 33. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis.
39 *Nat Rev Nephrol.* Dec 2009;5(12):713-21. doi:10.1038/nrneph.2009.184
- 40 34. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic
41 review. *Am J Physiol Renal Physiol.* Dec 1 2016;311(6):F1087-f1108.
42 doi:10.1152/ajprenal.00340.2016
- 43 35. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. *Curr Opin*
44 *Nephrol Hypertens.* Sep 2006;15(5):481-6. doi:10.1097/01.mnh.0000242172.06459.7c

- 1 36. Rosenstock JL, Pommier M, Stoffels G, Patel S, Michelis MF. Prevalence of Proteinuria
2 and Albuminuria in an Obese Population and Associated Risk Factors. *Front Med (Lausanne)*.
3 2018;5:122. doi:10.3389/fmed.2018.00122
- 4 37. Hemayati R, Kaseb F, Ghadiri-anari A, Yosefi F. The relationship between
5 microalbuminuria, overweight and obesity. *J Nephropathol*. 2020/10/1 2020;9(4):e41-e41.
6 doi:10.34172/jnp.2020.41
- 7 38. Basdevant A, Cassuto D, Gibault T, Raison J, Guy-Grand B. Microalbuminuria and body
8 fat distribution in obese subjects. *Int J Obes Relat Metab Disord*. Dec 1994;18(12):806-11.
- 9 39. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal
10 insufficiency prevalence guides population screening: results from the NHANES III. *Kidney Int*.
11 Jun 2002;61(6):2165-75. doi:10.1046/j.1523-1755.2002.00356.x
- 12 40. von Scholten BJ, Persson F, Svane MS, Hansen TW, Madsbad S, Rossing P. Effect of
13 large weight reductions on measured and estimated kidney function. *BMC Nephrol*. Feb 6
14 2017;18(1):52. doi:10.1186/s12882-017-0474-0
- 15 41. Navarro-Díaz M, Serra A, Romero R, Bonet J, Bayés B, Homs M, Pérez N, Bonal J.
16 Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese
17 patients: long-term follow-up. *J Am Soc Nephrol*. Dec 2006;17(12 Suppl 3):S213-7.
18 doi:10.1681/asn.2006080917
- 19 42. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss
20 on renal function in patients with severe obesity. *J Am Soc Nephrol*. Jun 2003;14(6):1480-6.
21 doi:10.1097/01.asn.0000068462.38661.89
- 22 43. Chang Y, Ryu S, Choi Y, Zhang Y, Cho J, Kwon MJ, Hyun YY, Lee KB, Kim H, Jung
23 HS, Yun KE, Ahn J, Rampal S, Zhao D, Suh BS, Chung EC, Shin H, Pastor-Barriuso R, Guallar
24 E. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study.
25 *Ann Intern Med*. Mar 1 2016;164(5):305-12. doi:10.7326/m15-1323
- 26 44. Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, Hobbs FD,
27 Coresh J, Woodward M. Body-mass index and risk of advanced chronic kidney disease:
28 Prospective analyses from a primary care cohort of 1.4 million adults in England. *PLoS One*.
29 2017;12(3):e0173515. doi:10.1371/journal.pone.0173515
- 30 45. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D,
31 Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A,
32 Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka
33 F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I. 2018 Practice Guidelines for
34 the management of arterial hypertension of the European Society of Cardiology and the
35 European Society of Hypertension. *Blood Press*. Dec 2018;27(6):314-340.
36 doi:10.1080/08037051.2018.1527177
- 37 46. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic
38 kidney disease. *Pediatr Nephrol*. Nov 2007;22(11):1839-48. doi:10.1007/s00467-006-0358-1
- 39 47. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and
40 estimated glomerular filtration rate. *N Engl J Med*. Jun 8 2006;354(23):2473-83.
41 doi:10.1056/NEJMra054415
- 42 48. Guebre-Egziabher F, Brunelle C, Thomas J, Pelletier CC, Normand G, Juillard L,
43 Dubourg L, Lemoine S. Estimated Glomerular Filtration Rate Bias in Participants with Severe
44 Obesity Regardless of Deindexation. *Obesity (Silver Spring)*. Dec 2019;27(12):2011-2017.
45 doi:10.1002/oby.22574

1 49. Tonneijck L, Muskiet MH, Smits MM, Van Bommel EJ, Heerspink HJ, Van Raalte DH,
2 Joles JA. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and
3 treatment. *Journal of the American Society of Nephrology*. 2017;28(4):1023-1039.

4 **Figure legends**

6 **Figure 1. Relationship between body weight, age and mCrCl**

7 Relationship between creatinine clearance and body weight (A) and age (B). In each panel, the
8 Pearson's correlation coefficient (r) is reported along with its significance (p)

9 **Figure 2. Relationship between mCrCl and the eCrCl**

10 Relationship between measured creatinine clearance and creatinine clearance estimated by CG
11 (A), CKD-EPI (B) and MDRD (C). Both CKD-EPI and MDRD were deindexed by multiplying
12 the results for BSA/1.73. In each panel, the Pearson's correlation coefficient (r) is reported along
13 with its significance (p).

14 **Figure 3. Relationship between mCrCl and CrCl estimated using the new formula.**

15 Pearson's correlation coefficient (r) is reported along with its significance (p)

17 **Figure 4. eCrCl by using the prediction formulas and mCrCl**

18 **Panel A.** Mean difference (\pm SD) between mCrCl and eCrCl by CG (+ 44.3 mL/min), CKD-EPI
19 (- 29.5 mL/min), MDRD (- 34.2 mL/min) and new formula (+ 0.3 mL/min).

20 *: $p < 0.05$ versus mCrCl as assessed by paired Student's t-test. N.S.: not significant

21 **Panel B.** Individual values of mCrCl and eCrCl by CG, CKD-EPI, MDRD and new formula.

22
23 Both CKD-EPI and MDRD formulas were deindexed by multiplying the results for BSA/1.73.

25 Abbreviations: CrCl: creatinine clearance; CG: Cockcroft-Gault formula; CKD-EPI: Chronic
26 Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal Disease

28 **Figure 5. Relationship between BMI and CrCl and prediction equations in the cohort of 29 342 patients with obesity and 50 healthy individuals without obesity**

30
31 Relationship between mCrCl and BMI in the cohort of 342 patients with obesity (black dots) and
32 in 50 healthy individuals without obesity (red dots). A spline curve fitted to the mCrCl is shown
33 together with the lines predicted by the conventional CG equation and by the modified CG
34 equation. The vertical dotted line indicates a BMI cutoff above which the eCrCl calculated using
35 the conventional CG formula was 7 mL/min higher than the mCrCl. This threshold was chosen
36 because it corresponds to the average difference between the mCrCl measurement and the
37 modified CG equation.

38
39
40

1 **Tables**

2 **Table 1. Summary of the formulas to measure and estimate the creatinine clearance**

3

CrCl (mL/min)	(24 h urinary creatinine × Urinary volume)/ Serum Creatinine
CKD-EPI (mL/min per 1.73 m²)	$141 \times \min(\text{Scr}/\kappa, 1)^\alpha \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}} \times 1.018$ [if female] $\times 1.159$ [if African American]
^ CKD-EPI (mL/min)	$141 \times \min(\text{Scr}/\kappa, 1)^\alpha \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}} \times 1.018$ [if female] $\times 1.159$ [if African American] $\times (\text{BSA}/1.73)$
MDRD (mL/min per 1.73 m²)	$175 \times (\text{SCr})^{-1.154} \times (\text{age})^{-0.203} \times 0.742$ [if female] $\times 1.212$ [if Black]
^ MDRD (mL/min)	$[175 \times (\text{SCr})^{-1.154} \times (\text{age})^{-0.203} \times 0.742$ [if female] $\times 1.212$ [if Black]] $\times (\text{BSA}/1.73)$
CG (mL/min)	$[(140 - \text{age}) (\text{weight in kg})/72 \times \text{serum creatinine}] \times 0.85$ if female

4

5

6 Abbreviations: BSA: body surface area; CrCl: creatinine clearance; CG: Cockcroft-Gault formula; CKD-

7 EPI: Chronic Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal

8 Disease; SCr: serum creatinine

9 For the CKD-EPI formula: κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for

10 males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1

11 **^** : deindexed eCrCl

12

13

14

15

16

17

18

1 **Table 2. Anthropometric and clinical measures, mCrCl and eCrCl in the study population**

2

	Men n=114	Women n= 228	Whole group n=342
Age (years)	49.0 ± 11.3	49.4 ± 13.1	49.2 ± 12.5
Body weight (kg)	148.5 ± 30.5*	122.5 ± 23.7	131.1 ± 28.8
Height (m)	1.74 ± 0.09*	1.61 ± 0.06	1.65 ± 0.09
BMI (kg/m²)	48.7 ± 9.5	47.0 ± 8.4	47.6 ± 8.9
BSA (m²)	2.31 ± 0.27*	2.52 ± 0.26	2.20 ± 0.21
Serum creatinine (mg/dL)	0.9 ± 0.2	0.72 ± 0.16*	0.78 ± 0.19
Urine creatinine (mg/24h)	2114 ± 587	1540 ± 470*	1732 ± 579
Urine volume (mL/24h)	1769 ± 770	1642 ± 761	1680 ± 764
mCrCl (mL/min)	170 ± 60	154 ± 59*	160 ± 60
eCrCl by CKD-EPI (mL/min per 1.73 m²)	97 ± 19	97 ± 20	97 ± 19
[^]eCrCl by CKD-EPI (mL/min)	143 ± 33	124 ± 30*	130 ± 32
eCrCl by MDRD (mL/min per 1.73 m²)	96 ± 25	92 ± 27	93 ± 26
[^]eCrCl by MDRD (mL/min)	140 ± 40	118 ± 38*	125 ± 40
eCrCl by CG (mL/min)	221 ± 80	195 ± 78*	204 ± 79
eCrCl by new formula (mL/min)	169 ± 42	155 ± 41*	160 ± 42

3


1 Data are presented as mean \pm SD. *: $p < 0.05$ between males and females as determined by unpaired
2 Student's *t*-test.

3 ^ : deindexed eCrCl was calculated by dividing individual eCrCl by 1.73 and by multiplying the result by
4 the BSA of each patient.

5
6 Abbreviations: BMI: body mass index; BSA: Body Surface Area; CG: Cockcroft-Gault; CKD-EPI:
7 Chronic Kidney Disease Epidemiology Collaboration; eCrCl: estimated creatinine clearance; MDRD:
8 Modification of Diet in Renal Disease; mCrCl: measured creatinine clearance
9

ACCEPTED MANUSCRIPT

1



2

3

4

5

Figure 1
169x77 mm (x DPI)

ACCEPTED MANUSCRIPT




Figure 2
214x77 mm (x DPI)

1
2
3
4

ACCEPTED MANUSCRIPT




Figure 3
112x102 mm (x DPI)

1
2
3
4





Figure 4
205x132 mm (x DPI)

1
2
3
4



1
2
3

Figure 5
152x109 mm (x DPI)